Chemotherapy-based regimens in multiple myeloma in 2020

Area of Science:

• Hematologic Oncology
• Malignancy Research
• Cancer Therapeutics

Background:

• Multiple myeloma (MM) is the second most common blood cancer.
• Early MM treatments included alkylating agents, anthracyclines, steroids, and high-dose chemotherapy with autologous stem cell transplantation.
• Significant advancements have been made with novel agents like proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and HDAC inhibitors.

Purpose of the Study:

• To review the evolution of multiple myeloma treatment strategies.
• To highlight the continued importance of older chemotherapeutic agents in modern MM therapy.
• To discuss the role of chemotherapy in specific MM scenarios and future directions.

Main Methods:

• Literature review of therapeutic approaches for multiple myeloma.
• Analysis of clinical trial data on various MM treatment regimens.
• Evaluation of the role of traditional chemotherapy in combination with novel agents.

Main Results:

• Novel drugs have significantly improved MM prognosis.
• Older chemotherapeutic drugs remain vital, particularly in combination regimens.
• Chemotherapy is essential for extramedullary MM manifestations and stem-cell mobilization.
• Melphalan is the gold standard for conditioning regimens.
• New agents like melflufen are under investigation.

Conclusions:

• The current MM treatment landscape integrates novel agents with established chemotherapy.
• Optimized combination therapies are key to improving outcomes in diverse MM presentations.
• Ongoing research into new chemotherapeutic agents promises further therapeutic advancements.